Summary: The capacity of L-649,923-sodium ( ßS, -yR * )-4-(3-( 4-acetyl-3-hydroxy-2-propylphenoxy)-propylthio)--y-hydroxy-ß-methylbenzene butanoate-to block vascular receptors of leukotriene D 4 ( L TD 4 ) was examined in the conscious rat. Hindquarter (HQ), renal, and mesenteric blood flow and vascular resistance were evaluated in the conscious rat chronically equipped with miniaturized Doppler probes for organ blood flow measurement by directional pulsed Doppler technique. In addition, cardiac outpul was measured by thermodilution technique in conscious rats equipped with minithermistors in the ascending aorta. Systemic hemodynamic variables. mean arterial pressure, and heart rate were monitored through femoral catheters. L TD 4 (I or 10 J.Lg/kg) produced a marked dose dependent increase in the mesenteric vascular resistance associated with a marked decrease in blood flow whereas no consistent effects were demonstrated in the renal circulation. L TD 4 • at I Cysteinylleukotrienes (LT) arepotent mediators produced by the 5-lipoxygenase pathway of arachidonate metabolism (I). The L Ts have been shown tobe extremely potent substances in producing pulmonary derangements (2,3) similar to the human disorder asthma (4), and to produce typical inflammatory reactions including wheal and tlare (5 ,6). Furthermore, LTs have been implicated in several trauma situations such as burns, hone fracture, and surgical wounds (7 -I 0) as weil as endotoxic shock ( 11, 12) . Cardiac and vascular derangements seem to be of primary importance in leukotriene-induced shock states (for review see ref. 13).
2/0
J.Lg/kg. increased the HQ blood flow whereas the higher dose of LTD 4 produced a biphasic response: an early increase followed by a decrease in blood flow. Infusion of L TD 4 • 3 J.Lg/kg per min over 10 min decreased cardiac output and increased total peripheral resistance. L-649,923 (10 or Several L T antagonists have already been tested and described in detail (for review see ref. 14) with the primary view of prophylactic or therapeutic capacity in asthma. However, alt the LT antagonists described so far demonstrated only limited potency and partial specificity. Furthermore, only a limited number of studies attempted to examine the capacity of LT antagonists to block the vascular receptors of L Ts. Vascular actions of such antagonists might be an essential part of a proteelive effect in situations where systemic cardiovascular derangements (e.g., cardiac anaphylaxis, shock) rather than pulmonary are the primary pathophysiologic processes.
Our laboratory has previously described the capacity of two known LT antagonists, FPL-55712 and LY-171883, toblock vascular responses to Dr. Eimerl's present address is Hadassah University Hospital, Jerusalem. Israel. LTD 4 and LTE 4 (15) . Whereas both compounds have demonstrated partial blocking capacity of the constrictive effect of L TD 4 on specific vascular beds. the doses that were necessary to produce the proteelive action were quite high and elicited intrinsic systemic and regional hemodynamic responses ( 15) .
More recently, a new LT antagonist. L-649,923. has been described (16) . This compound has been shown to be a competitive antagonist of the pulmonary effects of LTD 4 in vitro andin vivo (16) . However. the capacity of L-649,923 toblock cardiac and vascular LTD 4 receptors has not been studied as yet.
In this paper we have examined the capacity of L-649,923 to block LTD 4 actions on selected vascular beds and the cardiac output of the conscious rat. This species has been selected for these sturlies because LTs produce no consistent pulmonary effects and have no effect on platelet aggregation ( 17) . Furthermore. by utilizing the directional pulsed Doppler velocimetry for blood flow measurements it is possible to examine several discrete vascular responses instantaneously in the conscious state that cannot be accomplished by other methods.
MATERIALS AND METHODS
Male Sprague-Dawley rats (Taconic Farms) weighing 250-350 g were used in all studies (n = 26). Surgical procedures were performed under anesthesia after intramuscular injection of ketamine ( 130 mg/kg) and acepromazine ( 1.3 mg/kg) solution. Experiments were carried out on the conscious unrestrained rats 1-3 days after operation. All rats were housed individually in standard plastic cages with food and water ad libitum.
Regional blood flow measurements with directional pulsed Doppler technique
The directional pulsed Doppler method was selected to measure organ blood flow in the hindquarter. renal, and mesenteric vessels. Though it does not allow quantitative blood flow monitoring, this method is superior compared with other available techniques because: (a) it can be used chronically in conscious animals; (b) it allows continuous on-line recording of blood flow; and (c) it can detect instantaneous and transient changes in blood flood within seconds after the drug administration. Haywood et al. ( 18) have shown that the velocity signals recorded from the Doppler flow probes are directly and reliably proportional to changes in true volume flow measured by electromagnetic flowmetry.
Miniaturized Doppler flow probes were implanted around the lower abdominal aorta for hindquarter (HQ) blood tlow measurement. The superior mesenteric (M) and the left renal (R) arteries were also implanted with such probes by the method previously described by Haywood et al. (18) . Briefly. a midline laparotomy was performed, and the M, R, and Iower abdominal aorta above its bifurcation were carefully isolated under a dissecting microscope. Miniaturized Doppler flow probes (ValpeyFisher) were then loosely sutured (6-0 silk) around each vessel. The insulated wire Ieads of the probes were tunneled beneath the skin, exteriorized at the nape of the neck, and soldered to a receptacle that was then attached to the skull with small screws and dental acrylic. The femoral artery and vein were cannulated with polyethylene catheters (PE-50) that were also tunneled beneath the skin to exit at the neck. Catheters were regularly tlushed (0.2 ml) with heparinized saline ( 100 U/ml) and secured by a soft spring wire attahced to the animal's neck with an adhesive collar.
On the day of the experiment the arterialline was connected to a pressure transducer (Narco Bio-Systems model RP 1500i) coupled to a strain gauge coupler (Narco Bio-Systems type 7179) and a biotachometer coupler (Narco Bio-Systems type 7032). Mean arterial blood pressure (MAP) and heart rate (HR) were continuously recorded on a Narcotrace 80 computerized dynograph and sampled (automatically or manually) at 15-60 s intervals by a Northstar-Hazeltine computer. A connector line was attached between the blood flow receptacle and a directional pulsed Doppler flowmeter (University of Iowa, Bioelectrical Engineering). Output signals of Doppler shifts >4 kHz were simultaneously transformed to mean flow velocity (kHz) and recorded continuously on the Narcotrace 80 through universal couplers (type 7178). Local vascular resistance was calculated by dividing the MAP by the Doppler shift in kilohertz, as previously described ( 15) . lt is noteworthy that measurements of MAP from the femoral artery cannula in the rat are virtually the same as the MAP in other arteries (e.g., brachial, mesenteric) in normal, hypotensive, or hypertensive states (19) . Changes in regional blood flow and local vascular resistance were further expressed as percent changes from control values. No differences in the basal signallevel were found between the various experimental groups.
Experimental protocols
On the day of experiment each animal was allowed to stabilize for at least 30 min while basal (control) Ievels of the hemodynamic variables were recorded. Vehicle injections (0.9% NaCI, 300 ~L i.v.) were used as controls for injection effects. To assess the consistency of the various vascular responses, a bolus injection of norepinephrine (0.3-1 fJ.g/kg i. v .) was used; this test dose of norepinephrine caused a prompt increase in MAP, a decrease in HR, and a decreased blood flow in HQ. R. and M. After the stabilization period each animal was scheduled to one of the following protocols: (a) administration of L TD 4 
Measurement of cardiac output
In eight additional rats, the effect of L-649,923 on L TD 4 actions on cardiac outpul and total peripheral resistance (TPR) was investigated. Because bolus injections of L TD 4 induced only transient changes in hemodynamic variables that arenot possible to detect by using the thermodilution method, a continuous infusion of L TD 4 was used in these experiments. The rats were anesthetized with pentobarbitone (40 mg!kg i.p.) and PE-50 tubing was inserted into the femoral arteries. These catheters were tunneled beneath the back skin and exited at the back of the neck as previously described. An incision was made Significance from baseline: "P < 0.05, bp < 0.01 (Student-Newman-Keul test).
at the midline of the neck from the cricoid to the clavicle, and PE-50 tubing was inserted into the right atrium through the external jugular vein. The left common carotid artery was exposed and Jigated, and a thermistor (MX2-780-33 model THMP f 1.5, Teflon reusable, Columbus Instruments) was advanced through the carotid into the ascending aorta (placement above the aortic valve was confirmed in each animal at the end of the experiment and by the shape of the dilution curve). Alliines were secured by a soft spring wire through the cage as described earlier. Twenty-four hours after surgery, the arterial line was connected to a blood pressure transducer for hemodynamic recordings.
The cardiac output was measured by thermodilution technique as previously described (20) . ln brief, the thermistor was attached to the computerized Cardiomax II (CMX2-780-k with the miereprobe option R, Columbus Instruments). The dead space of the venous line was first ... 9% (wt/vo)) NaCI (saline) at room temperature (22°C); afterabrief stabilization period ( 10 s to ensure normal core ternperature) an additional injection of 0.2 ml normal saline {22°C) was rapidly injected using a 1 ml syringe. Cardiac output was recorded in the following way: a control period of 15 min included two to three cardiac output measurements to test for consistency and placement of the probe and also to get con- 
Statistics
Data are presented in text and figures as mean ± SEM for the indicated number of rats. Analysis of variance (ANOVA) with repeated measures and ANOVA followed by the Student Newman Keul test, Dunnett's test, or Kruskal-Wallis test was used for statistical evaluation of the data. Where appropriate, a two-tailed paired Student's t test was also used. Differences were considered significant when the p value was <0.05.
RESULTS
lnfluence of L-649, 923 on blood pressure and heart rate responses to LTD 4 L-649,923 at the higher dose (30 mg/kg i.v.) induced initial ( .. phase 1 ") hypotensive (-37 ± 5 mm Hg, p < 0.01) and strong bradycardic ( -135 ± 33 beats/min, p < 0.01) responses. These effects became apparent 30 s after the drug administration and were followed by the pressor effect ("phase 2"), which reached its maximum 5 min after the drug injection and subsided in 15 min (Table 1, Fig.  1 ). The baseline values of hemodynamic parameters immediately before L TD 4 administration were not different in L-649,923-treated rats compared with saline-treated rats (Table 2) . Intravenous injection of L TD 4 induced moderate increases in blood pressure and heart rate ( Fig. 1) . L-649,923 blocked the pressor response to the low dose of L TD 4 ( 1 !J.g/kg) but only partially attenuated the effect of the high dose (Fig. 2) .
Influence of L-649,923 on blood vessel responses to LTD 4 L-649,923 induced transient dilator/constrictor responses in HQ, R, and M blood vessels (Fig. 1,  Table 1 ). At the low dose (10 mg/kg) an initialrenal vasoconstriction followed by a vasodilation in all three vascular beds was observed whereas the higher dose (30 mg/kg) induced vasoconstriction in all three vascular beds. However, all these responses subsided within 5-l 0 min. The blood flow values before L TD 4 administration in L-649,923-treated animals did not significantly differ from Ievels after saline (Table 2) .
Bolus injection of LTD 4 produced differential effects on the R, M, and HQ vascular beds. In the mesenteric circulation (Fig. 3) LTD 4 (1 or 10 IJ.g/kg) produced pronounced vasoconstriction ( + 116 ± 44% and + 294 ± 69%, p < 0.01 vs. control), which was associated with marked reduction in mean blood tlow (-35 ± 9% and -64 ± 5%, p < 0.01 vs. control). L-649,923 (10 and 30 mg/kg, i.v.) com- pletely blocked the changes in MBF and mean vascular resistance (MVR) produced by the low dose of LTD 4 (I JJ.g/kg). The higher dose of L-649,923 also effectively blocked the effects of LTD 4 though not completely (Fig. 3) . In the HQ circulation, LTD 4 produced biphasic effects, i.e., an increase ( + 22 ± 5%, p < 0.01 vs.
control) in blood flow at the low dose followed by a decrease ( -16 ± 4%, p < 0.01 vs. control) at the higher dose. L-649,923 blocked only the secondary phase: the increase in hindquarter vascular resistance and decrease in hindquarter blood flow (Fig. 4) .
In the renal circulation, no statistically significant responses were monitored after L TD 4 , although a slight tendency for reduction of renal blood flow and an increase in renal vascular resistance was noticed. L-649,923 did not modify the LTD 4 effect in this region (Fig. 5) . Effect of L-649,923 on cardiac output response to LTD 4 infusion Infusion of L TD 4 to the conscious rat produced a slight increase in mean arterial pressure and heart rate (Fig. 6 ). These changes were not significantly affected by L-649,923. LTD 4 infusion produced a marked decrease in cardiac output that was accompanied by an increase in TPR (Fig. 7) ; both variables slowly returned to basal Ievels upon cessation of the infusion. L-649,923, at a dose of 30 mg/kg, did not significantly attenuate the initial decrease in cardiac output and the increase in TPR produced by LTD 4 infusion but totally blocked the later reduction in cardiac output and increase in TPR (Fig. 7) .
DISCUSSION
The cardiac and vascular responses produced by LTD 4 in this study are consistent with previous reports in the anesthetized and conscious rat (15, 17, 21 ,22) . The profound decrease in cardiac output is most probably the result of reduction in 0 2 delivery to the heart due to decrease in coronary blood flow because L TD 4 has been shown to produce profound coronary constriction in the rat coronary vessels (21) whereas no direct myocardial actions of LTD 4 were found in this species (23) . The vascular responses to LTD 4 in the rat are most probably mediated by L TD 4 receptors on the vascular smooth muscle because they are not blocked or modified by any antagonist of the known autacoids (24) nor are they mediated by cycloxygenase metabolites of arachidonic acid ( 15) .
The nature of the vascular receptors of L Ts has been only sparsely explored. Most of the pharmacologic sturlies using L T antagonists have focused on bronchopulmonary preparations or other nonvascular smooth muscles (e.g., ileal). However, blockade of the coronary and other vascular receptors to L Ts might be of critical importance in view of protecting the heart and other essential organs from the consequences of systemic anaphylaxis or other forms of tissue injury where large amounts of LTs are produced (7, 9, 10) .
The two LT antagonists, FPL-55712 and LY-171883, have been shown toblock the effect of L TD 4 at doses that already produce intrinsic cardiovascular effects ( 15) produced in the HQ, R, and M vessels in this same experimental model. Interestingly, LY-171883 but not FPL-55712 also blocked the vasodilation produced by L TD 4 or LTE 4 in the HQ (15) .
The newer L T antagonist tested in this study, L-649,923, produced clear dose dependent pressor effects in the conscious rat that followed abrief initial hypotension and bradycardia. Furthermore, L-649, 923 produced biphasic effects in the blood vessels tested. The low dose increased the blood tlow in the HQ, R, and M circulation, in part because of direct vasodilation; the higher dose produced a secondary constrictor response. The nature of the vasodilation and the secondary vasoconstriction produced by this drug is still obscure. Some intrinsic agonistic activity of L-649,923 might be preserved in this preferential antagonist of leukotrienes. Release of pressor mediators (e.g., catecholamines) is Contradieted by the finding that a profound hypotensive response accompanied the vasoconstriction. In any case, the hemodynamic responses provoked by L-649,923 were short Iasting and all the hemodynamic indexes were normal at the time of the LTD 4 administration.
L-649,923, at a dose of 30 mg/kg, completely blocked the increase in the mesenteric vascular resistance after I JLg/kg L TD 4 and preserved the tlow to the mesenteric region; this dose of L-649,923 still The actions of L-649,923 described in this model are most probably the result of the direct actions of L-649,923 on LT receptors. This conclusion is based on previous pharmacologic and biochemical sturlies showing that L-649,923 is a competitive L TD 4 antagonist and does not interact with histamine, serotonin, thromboxane A 2 , or other autacoid receptors (16) . Furthermore, in the rat, the effects of L TD 4 are independent of cyclooxygenase metabolites of arachidonate, histamine, acetylcholine, or catecholamines (15, 20) . However, the initial decrease in cardiac outpul and increase in TPR 3 min after the start of the L TD 4 infusion were not significantly blocked by L-649,923.
In summary, this study presents evidence on the (25) . However, further studies are necessary to fully explore the intrinsic activity of this compound and especially its potential acute constrictive effect on the coronary vessels.
